VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in ...
Thousands of consumers claim pharmaceutical companies and retailers negligently manufactured and stored ranitidine products ...
One of the largest pharmacy benefit management (PBM) companies in the United States has added VOQUEZNA (vonoprazan) tablets to its national formularies for commercial plans, effective immediately ...
Omeprazole ranks amongst the most frequently prescribed medications in the UK, with the latest figures revealing 73 million NHS prescriptions for proton pump inhibitors (PPIs), such as Omeprazole, ...
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA ...
Erosive GERD approval provides Phathom $175 million under its revenue interest financing agreement Conference call and webcast scheduled for November 2, 2023, at 11:00 a.m. ET FLORHAM PARK, N.J., Nov.
FLORHAM PARK, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback